Overview
The purpose of this study is to find out whether it is practical (feasible) to use a new type of imaging scan called 68Ga-FAPI PET/MRI (positron emission tomography/magnetic resonance imaging) to evaluate how well breast cancer responds to neoadjuvant chemotherapy.
Eligibility
Inclusion Criteria:
- Age ≥ 18
- ECOG Performance Status of ≤ 2
- Ability to review and signed informed consent
- Histologically confirmed, newly diagnosed invasive breast cancer
- Lymph node metastases (either histologically confirmed or radiographic evidence of lymph node metastases).
- Planned to undergo SOC NAC prior to surgical resection as outlined in section 4.1
Exclusion Criteria:
- Pregnancy or lactation.
- Patients who cannot undergo PET/MRI scanning because of:
- devices or implants that are not MRI safe
- hypersensitivity or known allergy to gadolinium-based contrast agents
- physical fitness not allowing scanning in prone for 30 minutes
- weight limits (450 lb. weight limit)
- Severe kidney disfunction (estimated GFR \< 30 ml/min/1.73 m2) (CKD-EPI (2021))
- Imaging features suspicious for concomitant in-situ cancer (LCIS/DCIS), such as nonbiopsied groups of microcalcifications
- Distant metastases (contraindication for NAC)
